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Abstract
Background: Plan adaptation during the course of (chemo)radiotherapy of H&N cancer requires repeat CT
scanning to capture anatomy changes such as parotid gland shrinkage. Hydration, applied to prevent
nephrotoxicity from cisplatin, could temporarily alter the hydrogen balance and hence the captured anatomy.
The aim of this study was to determine geometric changes of parotid glands as function of hydration during
chemoradiotherapy compared to a control group treated with radiotherapy only.
Methods: This study included an experimental group (n = 19) receiving chemoradiotherapy, and a control group
(n = 19) receiving radiotherapy only. Chemoradiotherapy patients received cisplatin with 9 l of saline solution during
hydration in the first, fourth and seventh week. The delineations of the parotid glands on the planning CT scan
were automatically propagated to Cone Beam CT scans using deformable image registration. Relative volume and
position of the parotid glands were determined at the second chemotherapy cycle (week four) and at fraction 35.
Results: When saline solution was administrated, the volume temporarily increased on the first day (7.2 %,
p < 0.001), second day (10.8 %, p < 0.001) and third day (7.0 %, p = 0.016). The gland positions shifted lateral, the
distance between glands increased on the first day with 1.5 mm (p < 0.001), on the second day 2.2 mm (p < 0.001).
At fraction 35, with both groups the mean shrinkage was 24 % ± 11 % (1SD) and the mean medial distance
between the parotid glands decreased by 0.47 cm ± 0.27 cm.
Conclusions: Hydration significantly modulates parotid gland geometry. Unless, in the context of adaptive RT, a
repeat CT scan is timed during a chemotherapy cycle, these effects are of minor clinical relevance.
Keywords: Head and neck cancer, Parotid glands, Anatomy changes, Adaptive radiotherapy
Background
Over the last few decades, chemoradiotherapy (CRT)
became the standard of care in patients with locally-
advanced head and neck (H&N) cancer (stage III/IV)
aiming at organ and function preservation. With CRT,
a cytostatic is used as a radiosensitizer enhancing the
damaging effect of radiotherapy (RT).
Cisplatin is a radiosensitizer that is often used in CRT
of H&N cancer. Besides its radiosensitizing effect, cis-
platin is known to have many side effects. Nephrotox-
icity is one important example. To reduce the risk of
nephrotoxicity, a substantial amount of saline solution is
administered to the patient before and after the adminis-
tration of cisplatin. This hydration during CRT of H&N
cancer can potentially alter the anatomy of the patient.
Several authors [1–9] described geometrical changes
of organs-at-risk (OARs) during treatment. The organ
most studied is the parotid gland (PG), showing a de-
crease of volume during treatment with a medial shift of
the center-of-mass [1–8]. The study of Bhide et al. [1]
demonstrated that the largest volume decrease occurs in
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the second week of treatment. No significant difference
was distinguished between the volume decrease of the
ipsi- and contralateral PG. Several studies pointed out
that the medio-lateral distance between the parotid
glands (PGs) decreases [1, 2, 6–8]. This shift sets in during
the second week of treatment with the largest displace-
ment during the fourth week [1].
Preliminary investigations on PG geometrical variabil-
ity in our institute showed an occasional increase of the
PG volume on Cone Beam CT (CBCT) scans of H&N
cancer patients treated with CRT. These patients were
all treated with concomitant cisplatin and received hy-
dration. Based on these findings it was hypothesized that
the geometry of the PGs is influenced by hydration dur-
ing CRT and this comparative study was designed.
Generally, the mean dose to the PGs is kept below
26Gy to prevent long term xerostomia and preserve
quality of life. The volume decrease and medial shift of
the PGs as described above, result in an increase of the
delivered dose [1, 3–6, 10]. Recently, adaptive RT has
emerged [11–13] where a repeat CT scan is acquired
and the treatment plan is adjusted to account for these
or other relevant geometrical changes and reduce tox-
icity. However, if the geometry of the PGs is influ-
enced by hydration, this needs to be taken into account,
in deciding when to make a repeat CT scan for adap-
tive RT.
The aim of this study was to determine geometric
changes of PGs as a function of hydration during
CRT compared to a control group treated with RT
only.
Methods
Patient and treatment characteristics
This retrospective study included 38 patients treated for
H&N cancer: an experimental group (n = 19) receiving
CRT and a control group (n = 19) receiving RT only. Pa-
tients with daily CBCT scans and the standard chemo-
therapy regime were selected. Patients in the CRT group
received cisplatin with hydration in the first, fourth and
seventh week of the treatment according to the RAD-
PLAT intravenous protocol: with each chemotherapy
cycle, 100 mg/m2 cisplatin with about 9 l of saline solu-
tion during hydration was administrated intravenously
in three days.
Both groups received a total dose of 70Gy on tumor
site in 35 fractions of 2Gy. For the CRT group, these
fractions were given in 7 weeks. Most patients in the RT
alone group received RT with an accelerated scheme of
6 weeks: once a week 2 fractions a day separated by a
time interval of at least 6 h. Further patient and treatment
characteristics are described in Table 1.
Treatment delivery and Cone Beam CT guidance protocol
All patients were positioned using a thermoplastic mask
(Orfit Industries, Wijnegem, Belgium), a standard head-
rest and a knee support (Civco Medical Solutions, Kolona,
USA). The planning CT (pCT) scan (Hispeed LX/I,
General Electric Medical Systems, Milwaukee, WI, USA
or Somatom Sensation Open, Siemens AG, Erlangen,
Germany) was acquired with a slice distance and thickness
of 3 mm from the cranium to the sternum. The patient
setup on the linear accelerator (Elekta, Synergy, Crawley,
Table 1 Patient and treatment characteristics
Patient characteristics CRT (n = 19) RT (n = 19) p
Gender Male 14 11 0.495
Female 5 8
Age in years Mean (range) 58 (42–71) 62 (47–81) 0.254
Tumor site Nasopharynx (T3-T4) 2 1 0.324
Oropharynx (T1-T4) 15 13
Hypopharynx (T2-T4) 2 2
Larynx (T2-T3) 0 3
pCT: PG volume (cm3) Mean (range) 20 (7–47) 24 (13–44) 0.082
pCT: medio-lateral distance between PGs (cm) Mean (range) 12 (10–13) 11 (10–13) 0.358
Planned dose ipsilateral PG (Gy) Mean 40.7 34.5 0.148
SD 11.7 12.2
Planned dose contralateral PG (Gy) Mean 27.2 23.0 0.122
SD 8.1 7.9
Body weight Mean pre-treatment (kg) 70 78 0.373
Mean loss (%) 7.9 5.6
Tube feeding Number of patients 15 6 0.008
CRT chemoradiotherapy group, RT radiotherapy alone group, pCT planning CT, PG(s) parotid gland(s)
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UK) was verified by registration of the bony anatomy from
the pCT to the CBCT using chamfer matching and was
corrected using a regular offline protocol [14]. Additional
CBCT scans were acquired for research purposes within
the context of other studies. A total of 1170 CBCT scans
were evaluated for this study with an average of 31 CBCT
scans per patient. CBCT scans were acquired over a
360° arc in 1 min (16 mA – 40 ms – 120 kV, per projec-
tion) with an isocenter dose of ~1 cGy.
Volume and center-of-mass
For each patient, the PGs were delineated on the pCT
scan. PG geometry during treatment was determined in
the CBCT scans by propagating these delineations using
deformable image registration (DIR). First the CBCT
scan was rigidly registered with the pCT scan on local
bony structures near the PGs. Next, soft tissue deforma-
tions were determined with DIR. An in-house developed
BSpline deformable registration algorithm was used [15].
The accuracy and precision of this algorithm is reviewed
in the discussion. Finally, the deformation fields were
used to propagate the delineations of the PGs from the
pCT to the CBCT scan.
Volume and center-of-mass (COM) of both PGs were
determined with the propagated delineations of the PGs
on the CBCT scans. The COM was given by x-, y- and
z-coordinates corresponding to the medio-lateral, dorso-
ventral and cranio-caudal direction.
Data analysis
Volume and position parameters of the PGs were calcu-
lated. Volume change was evaluated by dividing the PG
volume on the CBCT scan by the volume on the pCT
scan. According to Bhide et al. [1] no difference between
the volume decrease of the ipsi- and contralateral PG is
expected. Also both PGs received the same amount of
hydration. Therefore, we hypothesized that volumes
could be combined and the average volume of the two
PGs was calculated.
To obtain information on positional changes, the 3D
distance between the left and right PG was calculated by
subtracting the COMs. Subsequently, the distance be-
tween the PGs on the pCT scan was subtracted from the
distance on the CBCT scan. In this manner the pCT was
used as a reference to calculate relative volume and pos-
ition of the PGs with all CBCT scans that were acquired
during treatment.
Statistical analysis
The Mann–Whitney U-test was used to test for statis-
tical difference between relative volume of the ipsi- and
contralateral PG at treatment day 19 (just prior to the
second chemotherapy cycle). Baseline patient and treat-
ment characteristics (Table 1) were tested for statistical
difference between the CRT and RT alone group with
the Fisher’s Exact, Pearson Chi-Square or Mann–Whitney
U-test.
Relative volume and position of the PGs were tested
for statistical differences between the CRT and RT alone
group around the second chemotherapy cycle (week four)
and at the 35th fraction. For a statistical analysis there was
not enough information with the first chemotherapy cycle
(week 1: no CBCT scans prior to hydration) and the third
chemotherapy cycle (week 7: not sufficient CBCT scans in
the RT alone group due to the accelerated 6 week scheme
for most of these patient). For the analysis around the sec-
ond chemotherapy cycle, the starts of hydration for all
CRT patients were redefined as day 0 (usually Sundays).
For each patient, the difference in relative volume and
position between the days after start of hydration (day 1
till day 5) and the reference day (day −3; three days
before the start of hydration; baseline volume) was
calculated. The CRT group and RT alone group were
tested for statistical difference with a Mann–Whitney U-
test. P-values <0.05 were considered significant.
Results
Relative volume and position of the PGs during treat-
ment are presented in Fig. 1. In general, most patients
received their first fraction (treatment day 1) on Monday,
consequently there is too little data available on treatment
day 6, 7, 13, 14, etc. representing weekend days. Some
patients received their first fraction (treatment day 1) on
Tuesday or Wednesday, consequently the number of pa-
tients per treatment day with available CBCT scan varies
to at least 10.
At treatment day 19, just prior to the second chemo-
therapy cycle, the mean ipsilateral PG volume loss was
16 % ± 11 % (1SD) and the mean contralateral PG vol-
ume loss was 14 % ± 9 %. There was no significant differ-
ence between the relative volume of the ipsi- and
contralateral PG just prior to the second chemotherapy
cycle.
Table 1 presents patient and treatment characteristics
and summarizes the outcome of the statistical analysis.
The number of patients in the CRT group receiving tube
feeding was significantly higher compared to the RT alone
group (p = 0.008). Concerning other patient and treatment
characteristics there were no significant differences be-
tween the CRT and RT alone group.
At the intervals where saline solution was administered,
the volume of the PGs within the CRT group increased
temporarily and the position showed a temporal shift to a
more lateral position. Table 2 presents results of both pa-
tient groups at the time interval around the second
chemotherapy cycle (week four). Mean and median values
are comparable, indicating probably normally distrib-
uted data. Table 2 also summarizes the outcome of the
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statistical analysis. The relative change in volume of the
PGs was significantly different between groups on the first
day (7.2 %, p < 0.001), the second day (10.8 %, p < 0.001)
and the third day (7.0 %, p = 0.016) after starting hydration
(day 0) (Fig. 2). Maximum increase of the mean PG vol-
ume was seen on the second day after starting hydration
with 5.1 %. The relative change in position of the PGs in
medio-lateral direction was significantly different between
groups on the first (1.5 mm, p < 0.001) and second day
(2.2 mm, p < 0.001) after starting hydration (Fig. 3). Due
to hydration the movement in medial direction was re-
versed temporarily. No obvious shifts in dorso-ventral and
cranio-caudal directions were noticed.
At the day of the 35th fraction, the mean PG vol-
ume loss within the CRT group was 25 % ± 12 % (1SD)
and within the RT alone group 24 % ± 10 %. The PGs
shifted in medial direction; at the day of the 35th
fraction, the distance between the PGs decreased with
an average of 0.44 cm ± 0.26 cm within the CRT
group and with an average of 0.51 cm ± 0.27 cm
within the RT alone group. There was no significant
difference between the two groups regarding these overall
trends.
Discussion
PG volumes temporarily increase during hydration in
patients treated for H&N cancer with a high dose cis-
platin regimen in combination with RT. Moreover, the
medial shift is reversed just after the start of hydration.
When hydration was stopped, no significant differences
between the CRT and RT alone group, regarding both
volume and position of the PGs, were measured any-
more. Although the effects of hydration are temporary,
in the context of adaptive RT, caution should be taken in
timing a repeat CT scan. A repeat CT scan made at the
time of hydration will not be representative for the re-
maining fractions with respect to the PGs.
Overall during treatment, the PG volume decreased
and the PGs shifted in medial direction in both groups.
Previous studies [1–9] described a similar result. Han et
al. [5] performed a study including 5 patients who were
treated for H&N cancer with helical tomotherapy with
daily MVCT scans. The study described an average de-
crease of the PG volume of 1.1 % per treatment day. Ac-
cording to Bhide et al. [1] the average decrease in PG
volume was 1.1 % per day in the first four weeks of
treatment (31 % by week 4). For this study, 20 patients
Fig. 1 Overall volume and positional change of the parotid glands. Volumetric change of the parotid glands (PGs) (a) and distance change
between the PGs in medio-lateral direction (b) from the start of treatment. The black line corresponds to the average of the chemoradiotherapy
(CRT) group, the grey line corresponds to the average of the radiotherapy alone (RT) group. RT starts at treatment day 1. Saline solution was
administered during the first, second and third chemotherapy cycle, respectively during the first, fourth and seventh week of treatment (arrows).
Most patients in the RT alone group received RT with an accelerated scheme, therefore the grey line stops at week 6
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underwent a repeat CT scan in week 2, 3, 4 and 5 during
RT. In the study of Lee et al. [7], 10 patients were in-
cluded who were treated with helical tomotherapy with
daily MVCT scans. The study showed a median decrease
in volume of 0.4 to 1.3 % per day. In the study of Bhide
et al. [1] it appeared that the largest decrease in volume
takes place in the second week of the treatment. At the
end of treatment, mean PG volumes can decrease with
more than 50 %, i.e., Han et al. [5] found a decrease
of 59.8 % ± 17.4 % of the original volume. The PG
volume decrease with the patients of the current study is
smaller.
Vasquez et al. [8] showed that the lateral regions of
the glands move during RT while the medial regions are
relatively fixed. This would imply that a change of the
COM is more the result of volume change than an indi-
cator of positional change. Still, a movement of lateral
areas to a more medial position because of shrinkage
could increase the mean dose to the organ. Han et al. [5]
correlated an average decrease of the PG volume of
0.21 cm3 per treatment day with an average increase of
the dose to the PGs of 1.7 cGy per treatment day. Lee et
al. [6] correlated the COM change of the PGs with the
percent difference between plan and cumulative mean
dose. With the CRT group in the present study, decrease
of the PG volume and medial movement is temporarily
interrupted during hydration. Based on the study of Han
et al. [5] and Lee et al. [6], hypothetically the fraction dose
received by the PGs is temporarily reduced, with a limited
effect on the total dose. However, Bhide et al. [1] demon-
strated only a significant increase in mean dose to the ipsi-
lateral gland at week 4. When the mean dose to the PGs
were analyzed together it did not show a significant in-
crease in mean dose.
Our study has a number of limitations. First, the frac-
tionation schemes of the two groups differs. However, at
the end of week three, three days before the start of pre-
hydration of the second chemotherapy cycle, no signifi-
cant differences between the CRT and RT alone group,
regarding both relative volume and position of the PGs,
were measured.
Second, it was only possible to verify the volume and
position of the PGs during the second chemotherapy
cycle (week four). Although comparable trends were
seen during hydration of the first and third chemotherapy
cycle, respectively first and seventh week of treatment,
there wasn’t sufficient data for the applied method to con-
firm these findings. However, the timing of adaptive RT
will predominantly be mid-treatment, making our findings
relevant to clinical practice.
Third, the position of the PGs was specified with re-
spect to each other. Shifts in dorso-ventral and cranio-
Table 2 Effect of hydration on parotid gland volume and position during chemoradiotherapy
PG volume change relative to day−3 (%)
CRT RT CRT – RT
Mean Median Mean Median Mean Median p
day−3 86.3 87.7 86.7 87.1
day1 – day−3 +2.1 +1.8 −5.1 −4.5 7.2 6.3 <0.001
day2 – day−3 +5.1 +5.4 −5.6 −3.8 10.8 9.2 <0.001
day3 – day−3 +1.4 −1.8 −5.6 −4.7 7.0 2.8 0.016
day4 – day−3 −5.4 −6.9 −7.7 −7.3 2.2 0.4 0.601
day5 – day−3 −4.8 −4.8 −6.8 −6.7 2.0 1.9 0.511
Medio-lateral distance change between PGs relative to day−3 (cm)
CRT RT CRT – RT
Mean Median Mean Median Mean Median p
day−3 −0.24 −0.25 −0.30 −0.31
day1 – day−3 +0.06 +0.04 −0.09 −0.09 0.15 0.13 <0.001
day2 – day−3 +0.12 +0.09 −0.10 −0.08 0.22 0.17 <0.001
day3 – day−3 +0.03 +0.00 −0.09 −0.10 0.12 0.10 0.109
day4 – day−3 −0.08 −0.13 −0.14 −0.11 0.06 −0.02 0.718
day5 – day−3 −0.08 −0.08 −0.12 −0.12 0.03 0.04 0.554
Volume and position were determined from CBCT scans and expressed relative to the planning CT. Baseline volume and position were taken three days prior to
start of hydration in the second chemotherapy cycle (week 4). Hydration started around treatment day 21, this day was renamed day 0. Significance (Mann–
Whitney U-test) was tested against a control group receiving radiotherapy only. No significant results were found for the distance change between parotid glands
in dorso-ventral and cranio-caudal direction
PG(s) parotid gland(s), CRT chemoradiotherapy group, RT radiotherapy alone group
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caudal directions could be better specified if the position
of the PGs is measured in comparison with an immobile
structure, for example a bone structure. However, the
applied method is adequate to determine changes in
medial-lateral direction, which is the most relevant dir-
ection of positional change for the PGs.
Fourth, the planned dose on the ipsi- and contralateral
PG within both groups showed large variations (Table 1).
We did not take this into account in this study based on
the results of Bhide et al. [1]. He distinguished no sig-
nificant difference between the volume decrease of the
ipsi- and contralateral PG. To test this with our data, we
compared the relative volume of the ipsi- to the contra-
lateral PG at the end of week three: no significant differ-
ence was found. This confirms the observation of Bhide
et al. [1]. In addition, both the ipsi- and contralateral PG
are subjected to the same amount of hydration. This jus-
tifies combining the ipsi- and contralateral PG volume
for the purpose of the present study.
As a final limitation, we used DIR to propagate the
delineations from the pCT to the CBCT scans. With
DIR, uncertainties in accuracy are present. However, an
independent validation of the DIR algorithm that was
used in this study, by Mencarelli et al. [15] with gold
markers around the tumor showed submillimeter accur-
acy. Whereas, the precision was around 3 mm. Since the
precision is a random effect, this will not bias our results.
Furthermore, according to Lee et al. [7], geometrical
uncertainties of automatically generated contours are
comparable to those of manual contours. They concluded
that the deformable registration process provides a tool
for automatic evaluation of anatomical PG changes occur-
ring during treatment.
In this study, the influence of intravenous hydration,
consisting of 9 l in three days in combination with a 3
weekly cisplatin based CRT treatment, was verified. Differ-
ent amounts of fluid during hydration or a different CRT
scheme could have a different influence on volume and
position of PGs. Moreover, there are several other factors
that could be considered of having a possible influence on
the geometry of the PGs. For example: tumor volume,
tumor site, cytostatics, feeding status, BMI and gender
[1, 3–5, 16, 17]. These factors are not investigated in this
study. Possible influence of tube feeding on the geometry
of the PGs also is not investigated in this study.
Fig. 2 Volume change of the parotid glands during the fourth week
of treatment. Mean parotid gland volume for the chemoradiotherapy
(CRT) group and the radiotherapy alone (RT) group, relative to the start
of hydration (renamed day 0) during the second chemotherapy cycle
of the CRT group in the fourth week of treatment (a). Volumetric
change of the parotid glands between 3 days prior and 2 days after
starting hydration within the CRT group and the RT group (b)
Fig. 3 Positional change of the parotid glands during the fourth
week of treatment. Mean distance change between the parotid
glands (PGs) in medio-lateral direction for the chemoradiotherapy
(CRT) group and the radiotherapy alone (RT) group, relative to the
start of hydration (renamed day 0) during the second chemotherapy
cycle of the CRT group in the fourth week of treatment (a). Distance
change between the PGs in medio-lateral direction between 3 days
prior and 2 days after starting hydration within the CRT group and
the RT group (b)
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Conclusions
This study confirms overall PG shrinkage during (C)RT
and an overall decrease of the mean medial distance be-
tween the PGs. Hydration during high dose cisplatin based
CRT treatment of patients with H&N cancer, results in an
increase of the PG volume in combination with a lateral
movement of the COM. These effects of hydration are
small and temporary. Unless, in the context of adaptive
RT, a repeat CT scan is timed during a chemotherapy
cycle, these effects are of minor clinical relevance. How-
ever, since the effect of hydration on PG geometry has not
been investigated before, these results are relevant to share
with the research community.
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